{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:43:10Z","timestamp":1790044990852,"version":"4.0.1"},"reference-count":150,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Interstitial lung diseases (ILDs) are complex and heterogeneous diseases. The use of traditional diagnostic classification in ILD can lead to suboptimal management, which is worsened by not considering the molecular pathways, biological complexity, and disease phenotypes. The identification of specific \u201ctreatable traits\u201d in ILDs, which are clinically relevant and modifiable disease characteristics, may improve patient\u2019s outcomes. Treatable traits in ILDs may be classified into four different domains (pulmonary, aetiological, comorbidities, and lifestyle), which will facilitate identification of related assessment tools, treatment options, and expected benefits. A multidisciplinary care team model is a potential way to implement a \u201ctreatable traits\u201d strategy into clinical practice with the aim of improving patients\u2019 outcomes. Multidisciplinary models of care, international registries, and the use of artificial intelligence may facilitate the implementation of the \u201ctreatable traits\u201d approach into clinical practice. Prospective studies are needed to test potential therapies for a variety of treatable traits to further advance care of patients with ILD.<\/jats:p>","DOI":"10.1186\/s12931-023-02554-8","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T22:01:28Z","timestamp":1698098488000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Walking the path of treatable traits in interstitial lung diseases"],"prefix":"10.1186","volume":"24","author":[{"given":"Francesco","family":"Amati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Spagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Ryerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M.","family":"Oldham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gramegna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Stainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Mantero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Sverzellati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Lacedonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Richeldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Blasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Aliberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,24]]},"reference":[{"key":"2554_CR1","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733\u201348.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"2554_CR2","doi-asserted-by":"publisher","first-page":"682","DOI":"10.7326\/0003-4819-120-8-199404150-00010","volume":"120","author":"CS Bryan","year":"1994","unstructured":"Bryan CS. What is the Oslerian tradition? Ann Intern Med. 1994;120(8):682\u20137. https:\/\/doi.org\/10.7326\/0003-4819-120-8-199404150-00010.","journal-title":"Ann Intern Med"},{"key":"2554_CR3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1136\/thoraxjnl-2013-203602","volume":"69","author":"LEGW Vanfleteren","year":"2014","unstructured":"Vanfleteren LEGW, Kocks JWH, Stone IS, et al. Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms? Thorax. 2014;69:72\u20139.","journal-title":"Thorax"},{"key":"2554_CR4","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(15)60693-6","volume":"385","author":"PG Woodruff","year":"2015","unstructured":"Woodruff PG, Agusti A, Roche N, et al. Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet. 2015;385:1789\u201398.","journal-title":"Lancet"},{"key":"2554_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/msb4100163","volume":"3","author":"J Loscalzo","year":"2007","unstructured":"Loscalzo J, Kohane I, Barabasi AL. Human disease classification in the postgenomic era: a complex systems approach to human pathobiology. Mol Syst Biol. 2007;3:124.","journal-title":"Mol Syst Biol"},{"key":"2554_CR6","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S2213-2600(15)00254-4","volume":"3","author":"ED Bateman","year":"2015","unstructured":"Bateman ED, Reddel HK, van Zyl-Smit RN, et al. The asthma\u2013COPD overlap syndrome: a staging post to a revised taxonomy of chronic airways diseases? Lancet Respir Med. 2015;3:719\u201328.","journal-title":"Lancet Respir Med"},{"key":"2554_CR7","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S2213-2600(14)70047-5","volume":"2","author":"P Spagnolo","year":"2014","unstructured":"Spagnolo P, Grunewald J, du Bois RM. Genetic determinants of pulmonary fibrosis: evolving concepts. Lancet Respir Med. 2014;2:416\u201328.","journal-title":"Lancet Respir Med"},{"key":"2554_CR8","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0117-2017","volume":"27","author":"MA Kokosi","year":"2018","unstructured":"Kokosi MA, Margaritopoulos GA, Wells AU. Personalised medicine in interstitial lung diseases. Eur Respir Rev. 2018;27: 170117.","journal-title":"Eur Respir Rev"},{"issue":"6","key":"2554_CR9","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.chest.2021.12.668","volume":"161","author":"LJ De Sadeleer","year":"2022","unstructured":"De Sadeleer LJ, Verleden SE, Schupp JC, et al. BAL transcriptomes characterize idiopathic pulmonary fibrosis endotypes with prognostic impact. Chest. 2022;161(6):1576\u201388. https:\/\/doi.org\/10.1016\/j.chest.2021.12.668.","journal-title":"Chest"},{"issue":"3","key":"2554_CR10","doi-asserted-by":"publisher","first-page":"2002872","DOI":"10.1183\/13993003.02872-2020","volume":"57","author":"A Adegunsoye","year":"2021","unstructured":"Adegunsoye A, Morisset J, Newton CA, et al. Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis. Eur Respir J. 2021;57(3):2002872. https:\/\/doi.org\/10.1183\/13993003.02872-2020.","journal-title":"Eur Respir J."},{"key":"2554_CR11","doi-asserted-by":"publisher","first-page":"1802058","DOI":"10.1183\/13993003.02058-2018","volume":"53","author":"VM McDonald","year":"2019","unstructured":"McDonald VM, Fingleton J, Agusti A, et al. Treatable Traits: a new paradigm for 21st century management of chronic airway diseases. Eur Respir J. 2019;53:1802058.","journal-title":"Eur Respir J"},{"key":"2554_CR12","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1183\/13993003.01359-2015","volume":"47","author":"A Agusti","year":"2016","unstructured":"Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47:410\u20139.","journal-title":"Eur Respir J"},{"key":"2554_CR13","doi-asserted-by":"publisher","first-page":"1801269","DOI":"10.1183\/13993003.01269-2018","volume":"52","author":"R Boaventura","year":"2018","unstructured":"Boaventura R, Sibila O, Agusti A, et al. Treatable traits in bronchiectasis. Eur Respir J. 2018;52:1801269.","journal-title":"Eur Respir J"},{"issue":"2","key":"2554_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S2213-2600(23)00002-4","volume":"11","author":"F Amati","year":"2023","unstructured":"Amati F, Spagnolo P, Oldham JM, et al. Treatable traits in interstitial lung diseases: a call to action. Lancet Respir Med. 2023;11(2):125\u20138. https:\/\/doi.org\/10.1016\/S2213-2600(23)00002-4.","journal-title":"Lancet Respir Med"},{"key":"2554_CR15","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ebiom.2019.10.050","volume":"50","author":"AM Hoffmann-Vold","year":"2019","unstructured":"Hoffmann-Vold AM, Weigt SS, Saggar R, et al. Endotype-phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease. EBioMedicine. 2019;50:379\u201386.","journal-title":"EBioMedicine"},{"key":"2554_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-023-08969-x","author":"F Amati","year":"2023","unstructured":"Amati F, Bongiovanni G, Tonutti A, et al. Treatable traits in systemic sclerosis. Clin Rev Allergy Immunol. 2023. https:\/\/doi.org\/10.1007\/s12016-023-08969-x.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"2554_CR17","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.chest.2017.09.026","volume":"153","author":"A Adegunsoye","year":"2018","unstructured":"Adegunsoye A, Oldham JM, Chung JH, et al. Phenotypic clusters predict outcomes in a longitudinal interstitial lung disease cohort. Chest. 2018;153(2):349\u201360.","journal-title":"Chest"},{"key":"2554_CR18","first-page":"177","volume":"74","author":"L Hamman","year":"1944","unstructured":"Hamman L, Rich A. Acute diffuse interstitial fibrosis of the lungs. Bull Johns Hopkins Hosp. 1944;74:177\u2013212.","journal-title":"Bull Johns Hopkins Hosp"},{"key":"2554_CR19","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/00005792-195712000-00001","volume":"36","author":"E Rubin","year":"1957","unstructured":"Rubin E, Lubliner H. The Hamman-Rich syndrome: review of the literature and analysis of 15 cases. Medicine (Baltimore). 1957;36:397\u2013405.","journal-title":"Medicine (Baltimore)"},{"key":"2554_CR20","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/S0025-7125(16)33429-0","volume":"48","author":"LA Sheridan","year":"1964","unstructured":"Sheridan LA, Harrison JH Jr, Divertie MB. The current status of idiopathic pulmonary fibrosis (Hamman-Rich Syndrome). Med Clin N Am. 1964;48:993\u20131010.","journal-title":"Med Clin N Am"},{"key":"2554_CR21","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJM196406182702501","volume":"270","author":"EA Gaensler","year":"1964","unstructured":"Gaensler EA, Moister VB, Hamm J. Open-lung biopsy in diffuse pulmonary disease. N Engl J Med. 1964;270:1319\u201331.","journal-title":"N Engl J Med"},{"key":"2554_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000398285","volume":"8","author":"A Liebow","year":"1975","unstructured":"Liebow A. Definition and classification of interstitial pneumonias in human pathology. Prog Respir Dis. 1975;8:1\u201339.","journal-title":"Prog Respir Dis"},{"key":"2554_CR23","first-page":"1319","volume":"27","author":"G Todo","year":"1982","unstructured":"Todo G, Itoh H, Nakano Y, Dodo Y, Maeda H, Murata K, Odori T, Torizuka K, Izumi T, Oshima S. High-resolution CT (HR-CT) for the evaluation of pulmonary peripheral disorders. Jpn J Clin Imaging. 1982;27:1319\u201326.","journal-title":"Jpn J Clin Imaging"},{"key":"2554_CR24","doi-asserted-by":"crossref","unstructured":"ATS\/ERS. International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;165:277\u2013304.","DOI":"10.1164\/ajrccm.165.2.ats01"},{"key":"2554_CR25","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071\u201382.","journal-title":"N Engl J Med"},{"issue":"12","key":"2554_CR26","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","volume":"365","author":"L Richeldi","year":"2011","unstructured":"Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079\u201387. https:\/\/doi.org\/10.1056\/NEJMoa1103690.","journal-title":"N Engl J Med"},{"key":"2554_CR27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa030511","volume":"350","author":"G Raghu","year":"2004","unstructured":"Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004;350:125\u201333.","journal-title":"N Engl J Med"},{"issue":"9","key":"2554_CR28","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708\u201319. https:\/\/doi.org\/10.1016\/S2213-2600(16)30152-7.","journal-title":"Lancet Respir Med"},{"key":"2554_CR29","doi-asserted-by":"publisher","unstructured":"Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.\u00a0N Engl J Med. 2012;366(21):1968\u20131977. https:\/\/doi.org\/10.1056\/NEJMoa1113354","DOI":"10.1056\/NEJMoa1113354"},{"issue":"2","key":"2554_CR30","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1513\/AnnalsATS.201808-508CME","volume":"16","author":"AM Courtwright","year":"2019","unstructured":"Courtwright AM, El-Chemaly S. Telomeres in Interstitial Lung Disease: The Short and the Long of It. Ann Am Thorac Soc. 2019;16(2):175\u201381.","journal-title":"Ann Am Thorac Soc"},{"issue":"12","key":"2554_CR31","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1164\/rccm.201505-1010OC","volume":"192","author":"JM Oldham","year":"2015","unstructured":"Oldham JM, Ma SF, Martinez FJ, et al. TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2015;192(12):1475\u201382. https:\/\/doi.org\/10.1164\/rccm.201505-1010OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"2554_CR32","doi-asserted-by":"publisher","first-page":"1701875","DOI":"10.1183\/13993003.01875-2017","volume":"51","author":"A Justet","year":"2018","unstructured":"Justet A, Thabut G, Manali E, et al. Safety and efficacy of pirfenidone in patients carrying telomerase complex mutation. Eur Respir J. 2018;51(3):1701875. https:\/\/doi.org\/10.1183\/13993003.01875-2017.","journal-title":"Eur Respir J."},{"issue":"8","key":"2554_CR33","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S2213-2600(18)30135-8","volume":"6","author":"A Dressen","year":"2018","unstructured":"Dressen A, Abbas AR, Cabanski C, et al. Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study. Lancet Respir Med. 2018;6(8):603\u201314. https:\/\/doi.org\/10.1016\/S2213-2600(18)30135-8.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"2554_CR34","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1164\/rccm.201809-1646OC","volume":"200","author":"CA Newton","year":"2019","unstructured":"Newton CA, Zhang D, Oldham JM, et al. Telomere length and use of immunosuppressive medications in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2019;200(3):336\u201347.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2554_CR35","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12931-018-0769-0","volume":"19","author":"L Schwarzkopf","year":"2018","unstructured":"Schwarzkopf L, Witt S, Waelscher J, Polke M, Kreuter M. Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases\u2014a claims data analysis. Respir Res. 2018;19(1):73. https:\/\/doi.org\/10.1186\/s12931-018-0769-0.","journal-title":"Respir Res"},{"issue":"3","key":"2554_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151425","volume":"11","author":"M Kreuter","year":"2016","unstructured":"Kreuter M, Ehlers-Tenenbaum S, Palmowski K, et al. Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLoS ONE. 2016;11(3): e0151425. https:\/\/doi.org\/10.1371\/journal.pone.0151425.","journal-title":"PLoS ONE"},{"issue":"1","key":"2554_CR37","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1183\/09031936.00217614","volume":"46","author":"J Behr","year":"2015","unstructured":"Behr J, Kreuter M, Hoeper MM, et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur Respir J. 2015;46(1):186\u201396. https:\/\/doi.org\/10.1183\/09031936.00217614.","journal-title":"Eur Respir J"},{"issue":"21","key":"2554_CR38","doi-asserted-by":"publisher","first-page":"00292","DOI":"10.1016\/j.chest.2021.02.026","volume":"S0012\u20133692","author":"CT Lee","year":"2021","unstructured":"Lee CT, Adegunsoye A, Chung JH, et al. Characteristics and prevalence of domestic and occupational inhalational exposures across interstitial lung diseases. Chest. 2021;S0012\u20133692(21):00292. https:\/\/doi.org\/10.1016\/j.chest.2021.02.026.","journal-title":"Chest"},{"key":"2554_CR39","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1056\/NEJMp1500523","volume":"372","author":"FS Collins","year":"2015","unstructured":"Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793\u20135.","journal-title":"N Engl J Med"},{"key":"2554_CR40","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1056\/NEJMsb1503104","volume":"372","author":"JL Jameson","year":"2015","unstructured":"Jameson JL, Longo DL. Precision medicine\u2014personalized, problematic, and promising. N Engl J Med. 2015;372:2229\u201334.","journal-title":"N Engl J Med"},{"key":"2554_CR41","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jaci.2010.11.037","volume":"127","author":"J Lotvall","year":"2011","unstructured":"Lotvall J, Akdis CA, Bacharier LB, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011;127:355\u201360.","journal-title":"J Allergy Clin Immunol"},{"key":"2554_CR42","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1136\/thoraxjnl-2014-205507","volume":"69","author":"A Agusti","year":"2014","unstructured":"Agusti A. The path to personalized medicine in COPD. Thorax. 2014;69:857\u201364.","journal-title":"Thorax"},{"key":"2554_CR43","doi-asserted-by":"publisher","first-page":"L130","DOI":"10.1152\/ajplung.00070.2014","volume":"308","author":"A Ray","year":"2015","unstructured":"Ray A, Oriss TB, Wenzel SE. Emerging molecular phenotypes of asthma. Am J Physiol Lung Cell Mol Physiol. 2015;308:L130\u201340.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2554_CR44","doi-asserted-by":"publisher","first-page":"1901509","DOI":"10.1183\/13993003.01509-2019","volume":"55","author":"VM McDonald","year":"2020","unstructured":"McDonald VM, Clark VL, Cordova-Rivera L, et al. Targeting treatable traits in severe asthma: a randomised controlled trial. Eur Respir J. 2020;55:1901509.","journal-title":"Eur Respir J"},{"issue":"7","key":"2554_CR45","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/thoraxjnl-2012-202646","volume":"68","author":"VM McDonald","year":"2013","unstructured":"McDonald VM, Higgins I, Wood LG, Gibson PG. Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense? Thorax. 2013;68(7):691\u20134. https:\/\/doi.org\/10.1136\/thoraxjnl-2012-202646.","journal-title":"Thorax"},{"issue":"3","key":"2554_CR46","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/art.39971","volume":"69","author":"JA Zamora-Legoff","year":"2017","unstructured":"Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL. Progressive decline of lung function in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 2017;69(3):542\u20139.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"2554_CR47","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/rheumatology\/kex077","volume":"57","author":"S Reiseter","year":"2018","unstructured":"Reiseter S, Gunnarsson R, Mogens Aalokken T, Lund MB, Mynarek G, Corander J, et al. Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study. Rheumatology (Oxford). 2018;57(2):255\u201362.","journal-title":"Rheumatology (Oxford)"},{"issue":"150","key":"2554_CR48","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0077-2018","volume":"27","author":"AL Olson","year":"2018","unstructured":"Olson AL, Gifford AH, Inase N, Fern\u00e1ndez P\u00e9rez ER, Suda T. The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype. Eur Respir Rev. 2018;27(150): 180077.","journal-title":"Eur Respir Rev"},{"issue":"9","key":"2554_CR49","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","volume":"8","author":"PM George","year":"2020","unstructured":"George PM, Spagnolo P, Kreuter M, et al. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir Med. 2020;8(9):925\u201334. https:\/\/doi.org\/10.1016\/S2213-2600(20)30355-6.","journal-title":"Lancet Respir Med"},{"issue":"151","key":"2554_CR50","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0100-2018","volume":"28","author":"V Cottin","year":"2019","unstructured":"Cottin V, Wollin L, Fischer A, Quaresma M, Stowasser S, Harari S. Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir Rev. 2019;28(151): 180100. https:\/\/doi.org\/10.1183\/16000617.0100-2018.","journal-title":"Eur Respir Rev."},{"key":"2554_CR51","doi-asserted-by":"crossref","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9).","DOI":"10.1164\/rccm.202202-0399ST"},{"issue":"18","key":"2554_CR52","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718\u201327.","journal-title":"N Engl J Med"},{"key":"2554_CR53","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380:2518\u201328.","journal-title":"N Engl J Med"},{"issue":"5","key":"2554_CR54","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","volume":"8","author":"AU Wells","year":"2020","unstructured":"Wells AU, Flaherty KR, Brown KK, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020;8(5):453\u201360. https:\/\/doi.org\/10.1016\/S2213-2600(20)30036-9.","journal-title":"Lancet Respir Med"},{"issue":"9","key":"2554_CR55","doi-asserted-by":"publisher","first-page":"7849","DOI":"10.3390\/ijms24097849","volume":"24","author":"F Amati","year":"2023","unstructured":"Amati F, Stainer A, Polelli V, et al. Efficacy of pirfenidone and nintedanib in interstitial lung diseases other than idiopathic pulmonary fibrosis: a systematic review. Int J Mol Sci. 2023;24(9):7849. https:\/\/doi.org\/10.3390\/ijms24097849.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2554_CR56","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","volume":"8","author":"TM Maher","year":"2020","unstructured":"Maher TM, Corte TJ, Fischer A, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020;8(2):147\u201357. https:\/\/doi.org\/10.1016\/S2213-2600(19)30341-8.","journal-title":"Lancet Respir Med"},{"issue":"5","key":"2554_CR57","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","volume":"9","author":"J Behr","year":"2021","unstructured":"Behr J, Prasse A, Kreuter M, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9(5):476\u201386. https:\/\/doi.org\/10.1016\/S2213-2600(20)30554-3.","journal-title":"Lancet Respir Med"},{"key":"2554_CR58","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1378\/chest.12-2685","volume":"144","author":"ER Fernandez Perez","year":"2013","unstructured":"Fernandez Perez ER, Swigris JJ, Forssen AV, et al. Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. Chest. 2013;144:1644\u201351.","journal-title":"Chest"},{"key":"2554_CR59","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1164\/rccm.201608-1675PP","volume":"196","author":"ML Salisbury","year":"2017","unstructured":"Salisbury ML, Myers JL, Belloli EA, Kazerooni EA, Martinez FJ, Flaherty KR. Diagnosis and treatment of fibrotic hypersensitivity pneumonia. Where we stand and where we need to go. Am J Respir Crit Care Med. 2017;196:690\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"2554_CR60","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S2213-2600(16)30222-3","volume":"5","author":"CS King","year":"2017","unstructured":"King CS, Nathan SD. Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. Lancet Respir Med. 2017;5:72\u201384.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"2554_CR61","doi-asserted-by":"publisher","first-page":"1801587","DOI":"10.1183\/13993003.01587-2018","volume":"53","author":"SE Torrisi","year":"2019","unstructured":"Torrisi SE, Ley B, Kreuter M, et al. The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study. Eur Respir J. 2019;53(3):1801587.","journal-title":"Eur Respir J."},{"issue":"1","key":"2554_CR62","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/resp.14363","volume":"28","author":"T Karampitsakos","year":"2023","unstructured":"Karampitsakos T, Spagnolo P, Mogulkoc N, et al. Lung cancer in patients with idiopathic pulmonary fibrosis: a retrospective multicentre study in Europe. Respirology. 2023;28(1):56\u201365. https:\/\/doi.org\/10.1111\/resp.14363.","journal-title":"Respirology"},{"key":"2554_CR63","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1183\/13993003.02316-2014","volume":"46","author":"G Raghu","year":"2015","unstructured":"Raghu G, Amatto VC, Behr J, et al. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J. 2015;46:1113\u201330.","journal-title":"Eur Respir J"},{"key":"2554_CR64","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1136\/thoraxjnl-2016-208638","volume":"72","author":"LM Dowman","year":"2017","unstructured":"Dowman LM, McDonald CF, Hill CJ, et al. The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial. Thorax. 2017;72:610\u20139.","journal-title":"Thorax"},{"issue":"3","key":"2554_CR65","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/resp.12941","volume":"22","author":"O Nishiyama","year":"2017","unstructured":"Nishiyama O, Yamazaki R, Sano H, et al. Fat-free mass index predicts survival in patients with idiopathic pulmonary fibrosis. Respirology. 2017;22(3):480\u20135. https:\/\/doi.org\/10.1111\/resp.12941.","journal-title":"Respirology"},{"issue":"3","key":"2554_CR66","doi-asserted-by":"publisher","first-page":"1801289","DOI":"10.1183\/13993003.01289-2018","volume":"52","author":"J Pugashetti","year":"2018","unstructured":"Pugashetti J, Graham J, Boctor N, et al. Weight loss as a predictor of mortality in patients with interstitial lung disease. Eur Respir J. 2018;52(3):1801289.","journal-title":"Eur Respir J."},{"issue":"1","key":"2554_CR67","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12931-022-02159-7","volume":"23","author":"P Faverio","year":"2022","unstructured":"Faverio P, Fumagalli A, Conti S, et al. Sarcopenia in idiopathic pulmonary fibrosis: a prospective study exploring prevalence, associated factors and diagnostic approach. Respir Res. 2022;23(1):228. https:\/\/doi.org\/10.1186\/s12931-022-02159-7.","journal-title":"Respir Res"},{"issue":"5","key":"2554_CR68","doi-asserted-by":"publisher","first-page":"1900418","DOI":"10.1183\/13993003.00418-2019","volume":"53","author":"S Jouneau","year":"2019","unstructured":"Jouneau S, Lederlin M, Vernhet L, Thibault R. Malnutrition in idiopathic pulmonary fibrosis: the great forgotten comorbidity! Eur Respir J. 2019;53(5):1900418.","journal-title":"Eur Respir J."},{"issue":"1","key":"2554_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.healun.2014.06.014","volume":"34","author":"D Weill","year":"2015","unstructured":"Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014\u2014an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015;34(1):1\u201315.","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"2554_CR70","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1097\/TP.0000000000002901","volume":"104","author":"E Montgomery","year":"2020","unstructured":"Montgomery E, Macdonald PS, Newton PJ, et al. Frailty as a predictor of mortality in patients with interstitial lung disease referred for lung transplantation. Transplantation. 2020;104(4):864\u201372. https:\/\/doi.org\/10.1097\/TP.0000000000002901.","journal-title":"Transplantation"},{"issue":"4","key":"2554_CR71","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/resp.12944","volume":"22","author":"KM Milne","year":"2017","unstructured":"Milne KM, Kwan JM, Guler S, et al. Frailty is common and strongly associated with dyspnoea severity in fibrotic interstitial lung disease. Respirology. 2017;22(4):728\u201334. https:\/\/doi.org\/10.1111\/resp.12944.","journal-title":"Respirology"},{"key":"2554_CR72","doi-asserted-by":"publisher","DOI":"10.1111\/resp.14066.10.1111\/resp.14066","author":"MAM Farooqi","year":"2021","unstructured":"Farooqi MAM, O\u2019Hoski S, Goodwin S, et al. Prevalence and prognostic impact of physical frailty in interstitial lung disease: a prospective cohort. Respirology. 2021. https:\/\/doi.org\/10.1111\/resp.14066.10.1111\/resp.14066.","journal-title":"Respirology"},{"issue":"6","key":"2554_CR73","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1136\/thoraxjnl-2021-217361","volume":"77","author":"SA Guler","year":"2022","unstructured":"Guler SA, Hur SA, Stickland MK, et al. Survival after inpatient or outpatient pulmonary rehabilitation in patients with fibrotic interstitial lung disease: a multicentre retrospective cohort study. Thorax. 2022;77(6):589\u201395. https:\/\/doi.org\/10.1136\/thoraxjnl-2021-217361.","journal-title":"Thorax"},{"key":"2554_CR74","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/j.chest.2020.04.046","volume":"158","author":"CS King","year":"2020","unstructured":"King CS, Shlobin OA. The trouble with group 3 pulmonary hypertension in interstitial lung disease: dilemmas in diagnosis and the conundrum of treatment. Chest. 2020;158:1651\u201364.","journal-title":"Chest"},{"issue":"1","key":"2554_CR75","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Gali\u00e8","year":"2016","unstructured":"Gali\u00e8 N, Humbert M, Vachiery JL, et al. 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67\u2013119. https:\/\/doi.org\/10.1093\/eurheartj\/ehv317.","journal-title":"Eur Heart J"},{"issue":"4","key":"2554_CR76","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1056\/NEJMoa2008470","volume":"384","author":"A Waxman","year":"2021","unstructured":"Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med. 2021;384(4):325\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2008470.","journal-title":"N Engl J Med"},{"issue":"5","key":"2554_CR77","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.chest.2017.07.034","volume":"153","author":"CJ Winterbottom","year":"2018","unstructured":"Winterbottom CJ, Shah RJ, Patterson KC, et al. Exposure to ambient particulate matter is associated with accelerated functional decline in idiopathic pulmonary fibrosis. Chest. 2018;153(5):1221\u20138. https:\/\/doi.org\/10.1016\/j.chest.2017.07.034.","journal-title":"Chest"},{"key":"2554_CR78","doi-asserted-by":"publisher","first-page":"1801563","DOI":"10.1183\/13993003.01563-2018","volume":"53","author":"S Singh","year":"2019","unstructured":"Singh S, Collins BF, Bairwa M, et al. Hypersensitivity pneumonitis and its correlation with ambient air pollution in urban India. Eur Respir J. 2019;53:1801563.","journal-title":"Eur Respir J"},{"key":"2554_CR79","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1164\/rccm.201607-1484OC","volume":"195","author":"S Singh","year":"2017","unstructured":"Singh S, Collins BF, Sharma BB, et al. Interstitial lung disease in India. Results of a prospective registry. Am J Respir Crit Care Med. 2017;195:801\u201313.","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"2554_CR80","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1136\/thoraxjnl-2018-212877","volume":"74","author":"MB Rice","year":"2019","unstructured":"Rice MB, Li W, Schwartz J, et al. Ambient air pollution exposure and risk and progression of interstitial lung abnormalities: the Framingham Heart Study. Thorax. 2019;74(11):1063\u20139.","journal-title":"Thorax"},{"key":"2554_CR81","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1183\/09031936.00122213","volume":"43","author":"KA Johannson","year":"2014","unstructured":"Johannson KA, Vittinghoff E, Lee K, et al. Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure. Eur Respir J. 2014;43:1124\u201331.","journal-title":"Eur Respir J"},{"key":"2554_CR82","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.chest.2018.03.026","volume":"153","author":"LJ De Sadeleer","year":"2018","unstructured":"De Sadeleer LJ, Meert C, Yserbyt J, et al. Diagnostic ability of a dynamic multidisciplinary discussion in interstitial lung diseases: a retrospective observational study of 938 cases. Chest. 2018;153:1416\u201323.","journal-title":"Chest"},{"key":"2554_CR83","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1111\/resp.12850","volume":"21","author":"HE Jo","year":"2016","unstructured":"Jo HE, Glaspole IN, Levin KC, et al. Clinical impact of the interstitial lung disease multidisciplinary service. Respirology. 2016;21:1438\u201344.","journal-title":"Respirology"},{"key":"2554_CR84","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1513\/AnnalsATS.201811-794OC","volume":"16","author":"JS Grewal","year":"2019","unstructured":"Grewal JS, Morisset J, Fisher JH, et al. Role of a regional multidisciplinary conference in the diagnosis of interstitial lung disease. Ann Am Thorac Soc. 2019;16:455\u201362.","journal-title":"Ann Am Thorac Soc"},{"key":"2554_CR85","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1164\/ajrccm.158.6.9804105","volume":"158","author":"RW Tobin","year":"1998","unstructured":"Tobin RW, Pope Ii CE, Pellegrini CA, et al. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;158:1804\u201311.","journal-title":"Am J Respir Crit Care Med"},{"key":"2554_CR86","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1590\/S0004-28032011000200002","volume":"48","author":"RV Soares","year":"2011","unstructured":"Soares RV, Forsythe A, Hogarth K, et al. Interstitial lung disease and gastroesophageal reflux disease: key role of esophageal function tests in the diagnosis and treatment. Arq Gastroenterol. 2011;48:91\u20137.","journal-title":"Arq Gastroenterol"},{"issue":"12","key":"2554_CR87","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1513\/AnnalsATS.202001-035SD","volume":"17","author":"BR Wang","year":"2020","unstructured":"Wang BR, Edwards R, Freiheit EA, Ma Y, et al. The pulmonary fibrosis foundation patient registry. Rationale, design, and methods. Ann Am Thorac Soc. 2020;17(12):1620\u20138. https:\/\/doi.org\/10.1513\/AnnalsATS.202001-035SD.","journal-title":"Ann Am Thorac Soc."},{"issue":"2","key":"2554_CR88","doi-asserted-by":"publisher","first-page":"1601592","DOI":"10.1183\/13993003.01592-2016","volume":"49","author":"E Jo Helen","year":"2017","unstructured":"Jo Helen E, Ian G, Christopher G, et al. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Eur Respir J. 2017;49(2):1601592. https:\/\/doi.org\/10.1183\/13993003.01592-2016.","journal-title":"Eur Respir J"},{"issue":"9","key":"2554_CR89","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1164\/rccm.201807-1209PP","volume":"199","author":"E Farrand","year":"2019","unstructured":"Farrand E, Anstrom KJ, Bernard G, Butte AJ, Iribarren C, Ley B, et al. Closing the evidence gap in interstitial lung disease. The promise of real-world data. Am J Respir Crit Care Med. 2019;199(9):1061\u20135.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"2554_CR90","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s12016-018-8712-1","volume":"56","author":"ME Kuruvilla","year":"2019","unstructured":"Kuruvilla ME, Lee FE, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol. 2019;56(2):219\u201333. https:\/\/doi.org\/10.1007\/s12016-018-8712-1.","journal-title":"Clin Rev Allergy Immunol"},{"key":"2554_CR91","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/S0140-6736(02)11679-5","volume":"30","author":"RH Green","year":"2002","unstructured":"Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;30:1715\u201321.","journal-title":"Lancet"},{"issue":"9","key":"2554_CR92","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1164\/rccm.201709-1822LE","volume":"197","author":"A Papi","year":"2018","unstructured":"Papi A, Kostikas K, Wedzicha JA, et al. Dual bronchodilation response by exacerbation history and eosinophilia in the FLAME Study. Am J Respir Crit Care Med. 2018;197(9):1223\u20136. https:\/\/doi.org\/10.1164\/rccm.201709-1822LE.","journal-title":"Am J Respir Crit Care Med"},{"key":"2554_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107798","volume":"222","author":"P Spagnolo","year":"2021","unstructured":"Spagnolo P, Kropski JA, Jones MG, et al. Idiopathic pulmonary fibrosis: disease mechanisms and drug development. Pharmacol Ther. 2021;222: 107798. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107798.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"2554_CR94","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1378\/chest.12-0298","volume":"142","author":"AW Brown","year":"2012","unstructured":"Brown AW, Shlobin OA, Weir N, et al. Dynamic patient counseling: a novel concept in idiopathic pulmonary fibrosis. Chest. 2012;142(4):1005\u201310. https:\/\/doi.org\/10.1378\/chest.12-0298.","journal-title":"Chest"},{"issue":"5","key":"2554_CR95","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1378\/chest.09-0444","volume":"136","author":"EJ Kim","year":"2009","unstructured":"Kim EJ, Collard HR, King TE. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest. 2009;136(5):1397\u2013405.","journal-title":"Chest"},{"issue":"3","key":"2554_CR96","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/thoraxjnl-2013-203843","volume":"69","author":"SL Walsh","year":"2014","unstructured":"Walsh SL, Sverzellati N, Deveraj A, et al. Connective tissue disease related fibrotic lung disease: high resolution computer tomographic and pulmonary function indices as prognostic determinants. Thorax. 2014;69(3):216\u201322.","journal-title":"Thorax"},{"issue":"21","key":"2554_CR97","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1001\/jama.2013.5827","volume":"309","author":"AL Peljto","year":"2013","unstructured":"Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA. 2013;309(21):2232\u20139.","journal-title":"JAMA"},{"issue":"23","key":"2554_CR98","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1056\/NEJMoa1216076","volume":"368","author":"GM Hunninghake","year":"2013","unstructured":"Hunninghake GM, Hatabu H, Okajima Y, et al. MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med. 2013;368(23):2192\u2013200.","journal-title":"N Engl J Med"},{"issue":"6","key":"2554_CR99","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/ng.2609","volume":"45","author":"TE Fingerlin","year":"2013","unstructured":"Fingerlin TE, Murphy E, Zhang W, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet. 2013;45(6):613\u201320.","journal-title":"Nat Genet"},{"key":"2554_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.695919","volume":"8","author":"L Planas-Cerezales","year":"2021","unstructured":"Planas-Cerezales L, Arias-Salgado EG, Berastegui C, et al. Lung transplant improves survival and quality of life regardless of telomere dysfunction. Front Med (Lausanne). 2021;8: 695919.","journal-title":"Front Med (Lausanne)."},{"issue":"2","key":"2554_CR101","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1164\/rccm.201810-1891OC","volume":"200","author":"C Moore","year":"2019","unstructured":"Moore C, Blumhagen RZ, Yang IV, et al. Resequencing study confirms that host defense and cell senescence gene variants contribute to the risk of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2019;200(2):199\u2013208.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"2554_CR102","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S2213-2600(13)70045-6","volume":"1","author":"I Noth","year":"2013","unstructured":"Noth I, Zhang Y, Ma SF, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med. 2013;1(4):309\u201317.","journal-title":"Lancet Respir Med"},{"issue":"23","key":"2554_CR103","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1801562","volume":"379","author":"PA Juge","year":"2018","unstructured":"Juge PA, Lee JS, Ebstein E, et al. MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N Engl J Med. 2018;379(23):2209\u201319.","journal-title":"N Engl J Med"},{"issue":"2","key":"2554_CR104","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1055\/s-0034-1371527","volume":"35","author":"F Bonella","year":"2014","unstructured":"Bonella F, Costabel U. Biomarkers in connective tissue disease-associated interstitial lung disease. Semin Respir Crit Care Med. 2014;35(2):181\u2013200.","journal-title":"Semin Respir Crit Care Med"},{"issue":"3","key":"2554_CR105","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/resp.12920","volume":"22","author":"A Tzouvelekis","year":"2017","unstructured":"Tzouvelekis A, Herazo-Maya JD, Slade M, et al. Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis. Respirology. 2017;22(3):486\u201393.","journal-title":"Respirology"},{"issue":"2","key":"2554_CR106","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171344","volume":"12","author":"J Guiot","year":"2017","unstructured":"Guiot J, Henket M, Corhay JL, Moermans C, Louis R. Sputum biomarkers in IPF: evidence for raised gene expression and protein level of IGFBP-2, IL-8 and MMP-7. PLoS ONE. 2017;12(2): e0171344.","journal-title":"PLoS ONE"},{"issue":"6","key":"2554_CR107","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1378\/chest.124.6.2119","volume":"124","author":"R Janssen","year":"2003","unstructured":"Janssen R, Sato H, Grutters JC, et al. Study of Clara cell 16, KL-6, and surfactant protein-D in serum as disease markers in pulmonary sarcoidosis. Chest. 2003;124(6):2119\u201325.","journal-title":"Chest"},{"issue":"5","key":"2554_CR108","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.resinv.2019.03.006","volume":"57","author":"H Yamakawa","year":"2019","unstructured":"Yamakawa H, Hagiwara E, Ikeda S, et al. Evaluation of changes in the serum levels of Krebs von den Lungen-6 and surfactant protein-D over time as important biomarkers in idiopathic fibrotic nonspecific interstitial pneumonia. Respir Investig. 2019;57(5):422\u20139.","journal-title":"Respir Investig."},{"issue":"12","key":"2554_CR109","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.rmed.2015.10.005","volume":"109","author":"T Okamoto","year":"2015","unstructured":"Okamoto T, Fujii M, Furusawa H, Tsuchiya K, Miyazaki Y, Inase N. The usefulness of KL-6 and SP-D for the diagnosis and management of chronic hypersensitivity pneumonitis. Respir Med. 2015;109(12):1576\u201381.","journal-title":"Respir Med"},{"issue":"5","key":"2554_CR110","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1164\/ajrccm.162.5.9906096","volume":"162","author":"M Suga","year":"2000","unstructured":"Suga M, Iyonaga K, Okamoto T, et al. Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2000;162(5):1949\u201356.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1\u20132","key":"2554_CR111","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.cca.2009.09.034","volume":"411","author":"RG Boot","year":"2010","unstructured":"Boot RG, Hollak CE, Verhoek M, Alberts C, Jonkers RE, Aerts JM. Plasma chitotriosidase and CCL18 as surrogate markers for granulomatous macrophages in sarcoidosis. Clin Chim Acta. 2010;411(1\u20132):31\u20136.","journal-title":"Clin Chim Acta"},{"issue":"1","key":"2554_CR112","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13075-019-1835-9","volume":"21","author":"JS Lee","year":"2019","unstructured":"Lee JS, Lee EY, Ha YJ, Kang EH, Lee YJ, Song YW. Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease. Arthritis Res Ther. 2019;21(1):58.","journal-title":"Arthritis Res Ther"},{"key":"2554_CR113","doi-asserted-by":"publisher","first-page":"4759040","DOI":"10.1155\/2016\/4759040","volume":"2016","author":"K Hamai","year":"2016","unstructured":"Hamai K, Iwamoto H, Ishikawa N, et al. Comparative study of circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as disease markers of idiopathic pulmonary fibrosis. Dis Markers. 2016;2016:4759040.","journal-title":"Dis Markers"},{"issue":"5","key":"2554_CR114","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1378\/chest.11-2735","volume":"143","author":"JW Song","year":"2013","unstructured":"Song JW, Do KH, Jang SJ, Colby TV, Han S, Kim DS. Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest. 2013;143(5):1422\u20139.","journal-title":"Chest"},{"issue":"1","key":"2554_CR115","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.rmed.2010.09.012","volume":"105","author":"NM Korthagen","year":"2011","unstructured":"Korthagen NM, van Moorsel CH, Barlo NP, et al. Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis. Respir Med. 2011;105(1):106\u201313.","journal-title":"Respir Med"},{"issue":"8","key":"2554_CR116","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1164\/rccm.200808-1201OC","volume":"179","author":"A Prasse","year":"2009","unstructured":"Prasse A, Probst C, Bargagli E, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179(8):717\u201323.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"2554_CR117","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3899\/jrheum.120725","volume":"40","author":"A De Lauretis","year":"2013","unstructured":"De Lauretis A, Sestini P, Pantelidis P, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol. 2013;40(4):435\u201346.","journal-title":"J Rheumatol"},{"issue":"10","key":"2554_CR118","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.3899\/jrheum.160339","volume":"43","author":"M Kuwana","year":"2016","unstructured":"Kuwana M, Shirai Y, Takeuchi T. Elevated serum Krebs von den Lungen-6 in early disease predicts subsequent deterioration of pulmonary function in patients with systemic sclerosis and interstitial lung disease. J Rheumatol. 2016;43(10):1825\u201331.","journal-title":"J Rheumatol"},{"issue":"2","key":"2554_CR119","doi-asserted-by":"publisher","first-page":"1501924","DOI":"10.1183\/13993003.01924-2015","volume":"49","author":"X Long","year":"2017","unstructured":"Long X, He X, Ohshimo S, et al. Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis. Eur Respir J. 2017;49(2):1501924.","journal-title":"Eur Respir J"},{"issue":"2","key":"2554_CR120","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.chest.2016.03.004","volume":"150","author":"AM Hoffmann-Vold","year":"2016","unstructured":"Hoffmann-Vold AM, Tenn\u00f8e AH, Garen T, et al. High level of chemokine CCL18 is associated with pulmonary function deterioration, lung fibrosis progression, and reduced survival in systemic sclerosis. Chest. 2016;150(2):299\u2013306.","journal-title":"Chest"},{"issue":"4","key":"2554_CR121","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/1756-185X.13804","volume":"23","author":"S Kubo","year":"2020","unstructured":"Kubo S, Siebuhr AS, Bay-Jensen AC, et al. Correlation between serological biomarkers of extracellular matrix turnover and lung fibrosis and pulmonary artery hypertension in patients with systemic sclerosis. Int J Rheum Dis. 2020;23(4):532\u20139. https:\/\/doi.org\/10.1111\/1756-185X.13804.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"2554_CR122","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12931-021-01801-0","volume":"22","author":"H Jessen","year":"2021","unstructured":"Jessen H, Hoyer N, Prior TS, et al. Turnover of type I and III collagen predicts progression of idiopathic pulmonary fibrosis. Respir Res. 2021;22(1):205. https:\/\/doi.org\/10.1186\/s12931-021-01801-0.","journal-title":"Respir Res"},{"key":"2554_CR123","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12931-016-0343-6","volume":"17","author":"A Pardo","year":"2016","unstructured":"Pardo A, Cabrera S, Maldonado M, Selman M. Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis. Respir Res. 2016;17:23. https:\/\/doi.org\/10.1186\/s12931-016-0343-6.","journal-title":"Respir Res"},{"issue":"23","key":"2554_CR124","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1007\/s00018-017-2649-z","volume":"74","author":"DN O'Dwyer","year":"2017","unstructured":"O\u2019Dwyer DN, Moore BB. The role of periostin in lung fibrosis and airway remodeling. Cell Mol Life Sci. 2017;74(23):4305\u201314. https:\/\/doi.org\/10.1007\/s00018-017-2649-z.","journal-title":"Cell Mol Life Sci"},{"issue":"12","key":"2554_CR125","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1016\/j.cellsig.2015.09.003","volume":"27","author":"M Agassandian","year":"2015","unstructured":"Agassandian M, Tedrow JR, Sembrat J, et al. VCAM-1 is a TGF-\u03b21 inducible gene upregulated in idiopathic pulmonary fibrosis. Cell Signal. 2015;27(12):2467\u201373. https:\/\/doi.org\/10.1016\/j.cellsig.2015.09.003.","journal-title":"Cell Signal"},{"issue":"2","key":"2554_CR126","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1164\/rccm.201907-1343LE","volume":"201","author":"S Alqalyoobi","year":"2020","unstructured":"Alqalyoobi S, Adegunsoye A, Linderholm A, et al. Circulating plasma biomarkers of progressive interstitial lung disease. Am J Respir Crit Care Med. 2020;201(2):250\u20133. https:\/\/doi.org\/10.1164\/rccm.201907-1343LE.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"2554_CR127","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1164\/rccm.201309-1592OC","volume":"189","author":"LJ Vuga","year":"2014","unstructured":"Vuga LJ, Tedrow JR, Pandit KV, et al. C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014;189(8):966\u201374. https:\/\/doi.org\/10.1164\/rccm.201309-1592OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"2554_CR128","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1586\/17476348.2015.1062367","volume":"9","author":"I Campo","year":"2015","unstructured":"Campo I, Zorzetto M, Bonella F. Facts and promises on lung biomarkers in interstitial lung diseases. Expert Rev Respir Med. 2015;9(4):437\u201357. https:\/\/doi.org\/10.1586\/17476348.2015.1062367.","journal-title":"Expert Rev Respir Med"},{"issue":"6","key":"2554_CR129","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S2213-2600(21)00503-8","volume":"10","author":"WS Bowman","year":"2022","unstructured":"Bowman WS, Newton CA, Linderholm AL, et al. Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis. Lancet Respir Med. 2022;10(6):593\u2013602. https:\/\/doi.org\/10.1016\/S2213-2600(21)00503-8.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"2554_CR130","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1164\/rccm.202003-0877OC","volume":"203","author":"L Richeldi","year":"2021","unstructured":"Richeldi L, Scholand MB, Lynch DA, et al. Utility of a molecular classifier as a complement to high-resolution computed tomography to identify usual interstitial pneumonia. Am J Respir Crit Care Med. 2021;203(2):211\u201320.","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"2554_CR131","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/S2213-2600(20)30003-5","volume":"8","author":"SLF Walsh","year":"2020","unstructured":"Walsh SLF, Humphries SM, Wells AU, Brown KK. Imaging research in fibrotic lung disease; applying deep learning to unsolved problems. Lancet Respir Med. 2020;8(11):1144\u201353. https:\/\/doi.org\/10.1016\/S2213-2600(20)30003-5.","journal-title":"Lancet Respir Med"},{"issue":"4","key":"2554_CR132","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0215303","volume":"14","author":"SH Bak","year":"2019","unstructured":"Bak SH, Park HY, Nam JH, et al. Predicting clinical outcome with phenotypic clusters using quantitative CT fibrosis and emphysema features in patients with idiopathic pulmonary fibrosis [published correction appears in PLoS One. 2019 Jun 5;14(6):e0218223]. PLoS ONE. 2019;14(4): e0215303. https:\/\/doi.org\/10.1371\/journal.pone.0215303.","journal-title":"PLoS ONE"},{"issue":"1","key":"2554_CR133","doi-asserted-by":"publisher","first-page":"1601011","DOI":"10.1183\/13993003.01011-2016","volume":"49","author":"J Jacob","year":"2017","unstructured":"Jacob J, Bartholmai BJ, Rajagopalan S, et al. Mortality prediction in idiopathic pulmonary fibrosis: evaluation of computer-based CT analysis with conventional severity measures. Eur Respir J. 2017;49(1):1601011. https:\/\/doi.org\/10.1183\/13993003.01011-2016.","journal-title":"Eur Respir J."},{"issue":"11","key":"2554_CR134","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S2213-2600(18)30286-8","volume":"6","author":"SLF Walsh","year":"2018","unstructured":"Walsh SLF, Calandriello L, Silva M, Sverzellati N. Deep learning for classifying fibrotic lung disease on high-resolution computed tomography: a case-cohort study. Lancet Respir Med. 2018;6(11):837\u201345. https:\/\/doi.org\/10.1016\/S2213-2600(18)30286-8.","journal-title":"Lancet Respir Med"},{"issue":"11","key":"2554_CR135","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1513\/AnnalsATS.201612-947OC","volume":"14","author":"DG Pankratz","year":"2017","unstructured":"Pankratz DG, Choi Y, Imtiaz U, et al. Usual interstitial pneumonia can be detected in transbronchial biopsies using machine learning. Ann Am Thorac Soc. 2017;14(11):1646\u201354. https:\/\/doi.org\/10.1513\/AnnalsATS.201612-947OC.","journal-title":"Ann Am Thorac Soc"},{"issue":"6","key":"2554_CR136","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S2213-2600(19)30059-1","volume":"7","author":"G Raghu","year":"2019","unstructured":"Raghu G, Flaherty KR, Lederer DJ, et al. Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study. Lancet Respir Med. 2019;7(6):487\u201396. https:\/\/doi.org\/10.1016\/S2213-2600(19)30059-1.","journal-title":"Lancet Respir Med"},{"key":"2554_CR137","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/thoraxjnl-2012-202646","volume":"68","author":"VM McDonald","year":"2013","unstructured":"McDonald VM, Higgins I, Wood LG, Gibson PG. Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense? Thorax. 2013;68:691\u20134.","journal-title":"Thorax"},{"key":"2554_CR138","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1183\/09031936.00158507","volume":"33","author":"IN Park","year":"2009","unstructured":"Park IN, Jegal Y, Kim DS, et al. Clinical course and lung function change of idiopathic nonspecific interstitial pneumonia. Eur Respir J. 2009;33:68\u201376.","journal-title":"Eur Respir J"},{"key":"2554_CR139","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1183\/09031936.00094910","volume":"38","author":"M Romagnoli","year":"2011","unstructured":"Romagnoli M, Nannini C, Piciucchi S, et al. Idiopathic nonspecific interstitial pneumonia: an interstitial lung disease associated with autoimmune disorders? Eur Respir J. 2011;38:384\u201391.","journal-title":"Eur Respir J"},{"key":"2554_CR140","doi-asserted-by":"publisher","first-page":"28348","DOI":"10.3402\/ecrj.v2.28348","volume":"2","author":"E Bendstrup","year":"2015","unstructured":"Bendstrup E, Hyldgaard C, Altraja A, et al. Organisation of diagnosis and treatment of idiopathic pulmonary fibrosis and other interstitial lung diseases in the Nordic countries. Eur Clin Respir J. 2015;2:28348.","journal-title":"Eur Clin Respir J"},{"key":"2554_CR141","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.healthpol.2014.09.006","volume":"119","author":"J Prades","year":"2015","unstructured":"Prades J, Remue E, van Hoof E, et al. Is it worth reorganising cancer services on the basis of multidisciplinary teams (MDTs)? A systematic review of the objectives and organisation of MDTs and their impact on patient outcomes. Health Policy. 2015;119:464\u201374.","journal-title":"Health Policy"},{"key":"2554_CR142","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr","year":"2014","unstructured":"King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083\u201392.","journal-title":"N Engl J Med"},{"key":"2554_CR143","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","volume":"377","author":"PW Noble","year":"2011","unstructured":"Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760\u20139.","journal-title":"Lancet"},{"issue":"3","key":"2554_CR144","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1183\/09031936.00131912","volume":"42","author":"CJ Ryerson","year":"2013","unstructured":"Ryerson CJ, Urbania TH, Richeldi L, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J. 2013;42(3):750\u20137.","journal-title":"Eur Respir J"},{"key":"2554_CR145","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S2213-2600(15)00140-X","volume":"3","author":"SY Kim","year":"2015","unstructured":"Kim SY, Diggans J, Pankratz D, Huang J, Pagan M, Sindy N, et al. Classification of usual interstitial pneumonia in patients with interstitial lung disease: assessment of a machine learning approach using high-dimensional transcriptional data. Lancet Respir Med. 2015;3:473\u201382.","journal-title":"Lancet Respir Med"},{"issue":"147","key":"2554_CR146","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0110-2017.PMID:29436404;PMCID:PMC9489012","volume":"27","author":"G Noell","year":"2018","unstructured":"Noell G, Faner R, Agust\u00ed A. From systems biology to P4 medicine: applications in respiratory medicine. Eur Respir Rev. 2018;27(147): 170110. https:\/\/doi.org\/10.1183\/16000617.0110-2017.PMID:29436404;PMCID:PMC9489012.","journal-title":"Eur Respir Rev"},{"issue":"6","key":"2554_CR147","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2217\/pme.13.57","volume":"10","author":"M Flores","year":"2013","unstructured":"Flores M, Glusman G, Brogaard K, Price ND, Hood L. P4 medicine: how systems medicine will transform the healthcare sector and society. Per Med. 2013;10(6):565\u201376. https:\/\/doi.org\/10.2217\/pme.13.57.","journal-title":"Per Med"},{"key":"2554_CR148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1148\/radiol.2018181684","volume":"291","author":"H Hatabu","year":"2019","unstructured":"Hatabu H, Hunninghake GM, Lynch DA. Interstitial lung abnormality: recognition and perspectives. Radiology. 2019;291:1\u20133.","journal-title":"Radiology"},{"key":"2554_CR149","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.rmed.2018.02.001","volume":"136","author":"N Hoyer","year":"2018","unstructured":"Hoyer N, Wille MMW, Thomsen LH, et al. Interstitial lung abnormalities are associated with increased mortality in smokers. Respir Med. 2018;136:77\u201382.","journal-title":"Respir Med"},{"key":"2554_CR150","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1001\/jama.2016.0518","volume":"315","author":"RK Putman","year":"2016","unstructured":"Putman RK, Hatabu H, Araki T, et al. Association between interstitial lung abnormalities and all-cause mortality. JAMA. 2016;315:672\u201381.","journal-title":"JAMA"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02554-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-023-02554-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02554-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T08:27:58Z","timestamp":1700382478000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-023-02554-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,24]]},"references-count":150,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2554"],"URL":"https:\/\/doi.org\/10.1186\/s12931-023-02554-8","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,24]]},"assertion":[{"value":"25 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"F.A. reports personal fees and other from Boehringer Ingelheim, outside the submitted work. P.S. reports grants and personal fees from Roche, grants, personal fees and non-financial support from PPM Services, personal fees from Galapagos, personal fees from Chiesi, grants, personal fees and non-financial support from Boehringer-Ingelheim, personal fees from Santhera Pharmaceuticals, personal fees from Lupin Pharmaceuticals, personal fees from Novartis, personal fees from Pieris Pharmaceuticals, outside the submitted work; and Wife employee of Novartis. C.R. reports grants and personal fees from Boehringer Ingelheim, personal fees from Hoffmann-La Roche, outside the submitted work. J.O. reports grants from National Institutes of Health, grants from Boehringer Ingelheim, during the conduct of the study; personal fees from Boehringer Ingelheim, personal fees from Roche\/Genentech, other from Novartis, other from Endeavor BioMedicines, other from Genenetch, personal fees from Lupin Pharmaceuticals, personal fees from Gatehouse Bio, outside the submitted work. A.G. is an editorial board member of Respiratory Research. A.S. reports other from Boehringer Ingelheim, other from Roche, outside the submitted work. M.M. reports personal fees and other from Boehringer Ingelheim, outside the submitted work. N.S. has nothing to disclose. D.L. reports personal fees from Roche, personal fees from Boehringer Ingelheim, outside the submitted work. L.R. reports personal fees from Biogen, grants and personal fees from Roche, personal fees from ImmuneWorks, grants and personal fees from Boehringer Ingelheim, personal fees from Celgene, personal fees from Nitto, personal fees from FibroGen, personal fees from Promedior, personal fees from Pliant Therapeutics, personal fees from Asahi Kasei, personal fees from Toray, personal fees from BMS, personal fees from RespiVant, personal fees from CSL Behring, outside the submitted work. F.B. reports grants and personal fees from Astrazeneca, personal fees from Chiesi, personal fees from Glaxosmithkline, personal fees from Grifols, personal fees from Guidotti, grants and personal fees from Insmed, grants and personal fees from Menarini, personal fees from Novartis, personal fees from om pharma, personal fees from Pfizer, personal fees from Sanofi, personal fees from vertex, personal fees from Viatris, personal fees from Zambon, outside the submitted work. F.B is an editorial board member of Respiratory Research. S.A. reports personal fees from Bayer Healthcare, personal fees from Grifols, personal fees from Astra Zeneca, personal fees from Zambon, grants and personal fees from Chiesi, grants and personal fees from INSMED, personal fees from GlaxoSmithKline, personal fees from Menarini, personal fees from ZetaCube Srl, grants from Fisher & Paykel, outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"251"}}